var data={"title":"Etanercept (including biosimilars of etanercept): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Etanercept (including biosimilars of etanercept): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6147?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">see &quot;Etanercept (including biosimilars of etanercept): Drug information&quot;</a> and <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-patient-drug-information\" class=\"drug drug_patient\">see &quot;Etanercept (including biosimilars of etanercept): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6655343\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Serious infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Patients treated with etanercept are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients treated with etanercept who developed these infections were taking concomitant immunosuppressants, such as methotrexate or corticosteroids.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue etanercept if a patient develops a serious infection or sepsis.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Reported infections include the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before etanercept use and during therapy. Initiate treatment for latent infection prior to etanercept use.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Bacterial, viral, and other infections caused by opportunistic pathogens, including Legionella and Listeria.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Carefully consider the risks and benefits of treatment with etanercept prior to initiating therapy in patients with long-term or recurrent infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Closely monitor patients for the development of signs and symptoms of infection during and after treatment with etanercept, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancies:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167887\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Enbrel;</li>\n      <li>Enbrel Mini;</li>\n      <li>Enbrel SureClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167888\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Brenzys;</li>\n      <li>Enbrel;</li>\n      <li>Erelzi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047265\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Tumor Necrosis Factor (TNF) Blocking Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047258\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">see &quot;Etanercept (including biosimilars of etanercept): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Erlezi (etanercept-szzs) is approved as a biosimilar to Enbrel. Approved uses for biosimilar agents may vary (consult product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis:</b> Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Once-weekly dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &lt;63 kg: Enbrel: SubQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose<b>. Note:</b> Although FDA approved in patients &ge;2 years of age, Erlezi does not have a dosage form that would allow for dosing in patients &lt;63 kg.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight &ge;63 kg: Enbrel, Erlezi: SubQ: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Twice-weekly dosing:</i> SubQ: 0.4 mg/kg/dose twice weekly, given 72 to 96 hours apart; maximum dose: 25 mg/dose (Lovell 2006); <b>Note:</b> Trials performed with Enbrel product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Kawasaki disease; acute, adjunct therapy:</b> Limited data available (AHA [McCrindle 2017]): Infants &ge;6 months and Children &lt;6 years: SubQ: 0.8 mg/kg/dose for 3 doses; administer first dose within 24 hours after completion of IV immunoglobulin (day 0), the second dose at day 7, and third dose at day 14; maximum dose: 50 mg/dose. Dosing based on an open-labeled pilot trial of 15 pediatric patients (mean age: 2.6 years); all patients also received standard aspirin therapy; no patients required retreatment or rescue therapy for signs/symptoms of Kawasaki disease (Choueiter 2010). A large double-blind, placebo-controlled trial is ongoing [EATAK trial (NCT00841789)] utilizing the same dosage regimen; results pending (Portman 2011). <b>Note:</b> Trials performed with Enbrel product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mediterranean fever; familial (FMF) (intolerance or resistance to colchicine):</b> Very limited data available; efficacy results variable: Children &ge;11 years and Adolescents: SubQ: 0.8 mg/kg once weekly; maximum dose: 50 mg/dose; dosing based on a case series (n=3); results showed fewer attacks with treatment, median duration of therapy was 3 months and all patients continued colchicine therapy if able; over time, therapy was eventually changed to anakinra due to clinician determined unsatisfactory response (Akgul 2012; &Ouml;zen 2011; Sakallioglu 2006; Soriano 2013); a case series in adult patients (n=5, age range: 20 to 40 years) reported no further attacks (80%) or decrease frequency (20%) with etanercept (25 mg twice weekly) therapy (Bilgen 2011). <b>Note:</b> Studies performed with Enbrel product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plaque psoriasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 4 to 17 years Enbrel: SubQ: 0.8 mg/kg/dose once weekly; maximum dose: 50 mg/dose; results of a long-term study (264 weeks) showed efficacy maintained and therapy generally well-tolerated (Paller 2008; Paller 2010; Paller 2016; Siegfried 2010); <b>Note:</b> Studies performed with Enbrel product.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;18 years: Enbrel, Erlezi: SubQ: Initial: 50 mg twice weekly administered 72 to 96 hours apart for 3 months; <b>Note:</b> Initial doses of 25 mg or 50 mg per week were also shown to be efficacious; maintenance dose: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:</b> Adolescents &ge;18 years: Enbrel, Erlezi:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-weekly dosing: SubQ: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twice-weekly dosing: SubQ: 25 mg twice weekly (individual doses should be separated by 72 to 96 hours); maximum amount administered at a single injection site: 25 mg; rheumatoid arthritis: Maximum weekly dose: 50 mg/week (Bathon 2000; Calin 2004; Davis 2003; Genovese 2002; Mease 2000; Mease 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Plaque psoriasis:</b> SubQ: Initial: 50 mg twice weekly (administered 72 to 96 hours apart) for 3 months; <b>Note:</b> Initial doses of 25 mg or 50 mg per week were also shown to be efficacious; maintenance dose: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:</b> SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Once-weekly dosing: 50 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Twice-weekly dosing: 25 mg given twice weekly (Bathon 2000; Calin 2004; Davis 2003; Genovese 2002; Mease 2000; Mease 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167868\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel SureClick: 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel Mini: 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel: 25 mg/0.5 mL (0.51 mL); 50 mg/mL (0.98 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enbrel: 25 mg (1 ea) [contains benzyl alcohol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167854\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48847984\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Erelzi (etanercept-szzs): FDA approved August 2016; anticipated availability is currently unknown. Erelzi is approved as biosimilar to Enbrel, but not as an interchangeable product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874648\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103795s5561lbl.pdf#page=34&amp;token=TlvsGN6yU3iu7E1WHJZFY10u0eNNUj+cPVADoN+JE+4xeDvyf7dE4wvUB7Ltg9+2bE+lyslP5WRGuhw8LwGy5+Abc0bgQfnSZil8NFS3pLmXrl+ij1K3/MMCNEGEkKf1&amp;TOPIC_ID=13284\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103795s5561lbl.pdf#page=34</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047268\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer subcutaneously into front of the thigh (preferred), abdomen (avoiding the area around the navel [2 inches in adults]), or outer area of the upper arm. Rotate injection sites. New injections should be given at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard or into any raised thick, red, or scaly skin patches or lesions. For a more comfortable injection, autoinjectors, prefilled syringes, and dose trays may be allowed to reach room temperature by removing from the refrigerator 15 to 30 minutes prior to injection. <b>Note:</b> If the prescriber determines that it is appropriate, patients may self-inject after proper training in injection technique.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple-use vial (Enbrel): Do not administer &gt;25 mg at a single injection site if the multiple-use vial is used to prepare the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single-use prefilled syringe or autoinjector (Enbrel, Erlezi): Do not remove needle cover or needle shield while allowing to reach room temperature. Visually inspect for particulate matter and discoloration prior to administration; solution may have small white particles of protein, which is normal for a proteinaceous solution; should not be used if cloudy, discolored or if foreign matter is present.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167883\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not shake. Do not freeze or store in extreme heat or cold. Store in the original carton to protect from light or physical damage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Individual autoinjectors, prefilled syringes, dose trays (containing multi-use vials and diluent syringes), or prefilled pens may be stored between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F) for a maximum single period of 14 days (Enbrel) or 28 days (Erelzi) with protection from light and sources of heat and humidity. Once an autoinjector, prefilled syringe, dose tray, or prefilled pen has been stored at room temperature, it should not be placed back into the refrigerator; discard after 14 days (Enbrel) or 28 days (Erelzi).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Once the multi-use vial has been reconstituted, use the reconstituted solution immediately or refrigerate at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not store at room temperature. Reconstituted solution must be discarded after 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047267\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of moderately- to severely-active polyarticular juvenile idiopathic arthritis (Enbrel, Erelzi; FDA approved in ages &ge;2 years); treatment of signs and symptoms of moderately- to severely-active rheumatoid arthritis, psoriatic arthritis, and active ankylosing spondylitis (Enbrel, Erelzi; FDA approved in adults); treatment of chronic (moderate to severe) plaque psoriasis in patients who are candidates for systemic therapy or phototherapy (Enbrel FDA approved in ages &ge;4 years and adults; Erelzi: FDA approved in adults); has also been used as adjunctive therapy Kawasaki disease and for treatment of familial Mediterranean fever (colchicine refractory or colchicine intolerant), scleroderma, and chronic nonbacterial osteomyelitis</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> Erelzi (etanercept-szzs) is approved as a biosimilar agent. Approved uses may vary (consult product labeling).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914269\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Enbrel may be confused with Levbid</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167917\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Cellulitis, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, gastroenteritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, infection, influenza, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (more common in adults; bleeding, bruising, erythema, itching, pain, or swelling; mild to moderate and usually decreases with subsequent injections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Osteomyelitis, septic arthritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, pneumonia, respiratory tract infection, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Antibody development (non-neutralizing), fever, positive ANA titer</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anemia, angioedema, aplastic anemia, aseptic meningitis, aspergillosis, autoimmune hepatitis, cardiac failure, chest pain, cutaneous lupus erythematous, demyelinating disease of the central nervous system, erythema multiforme, fungal infection (including histoplasmosis), Guillain-Barr&eacute; syndrome, hepatotoxicity (idiosyncratic) (Chalasani 2014), herpes zoster, increased serum transaminases, inflammatory bowel disease, interstitial pulmonary disease, leukemia, leukopenia, lupus-like syndrome, lymphadenopathy, malignant lymphoma, malignant melanoma, malignant neoplasm, Merkel cell carcinoma, multiple sclerosis, neutropenia, optic neuritis, pancytopenia, paresthesia, pneumonia due to <i>Pneumocystis carinii</i>, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), reactivation of HBV, sarcoidosis, scleritis, seizure, skin carcinoma, Stevens-Johnson syndrome, subcutaneous nodule, thrombocytopenia, toxic epidermal necrolysis, transverse myelitis, tuberculosis (including pulmonary and extrapulmonary), uveitis, varicella zoster infection, vasculitis (cutaneous and systemic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167873\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to etanercept or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167858\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions may occur, if an anaphylactic reaction or other serious allergic reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, have been reported; monitor and discontinue if symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Demyelinating CNS disease: Rare cases of new-onset or exacerbation of CNS demyelinating disorders have occurred; may present with mental status changes and some may be associated with permanent disability. Optic neuritis, transverse myelitis, multiple sclerosis, Guillain-Barr&eacute; syndrome, and other peripheral demyelinating neuropathies have been reported. Use with caution in patients with preexisting or recent-onset CNS demyelinating disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Worsening and new-onset heart failure has been reported, including in patients without known preexisting cardiovascular disease. Use with caution in patients with heart failure or decreased left ventricular function. In a scientific statement from the American Heart Association, TNF blockers have been determined to be agents that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic disorders: Rare cases of pancytopenia and aplastic anemia have been reported (some fatal). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed. Use with caution in patients with a history of significant hematologic abnormalities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants (has been fatal); evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; consider interruption of therapy if reactivation occurs and treat appropriately with antiviral therapy. If resumption of therapy is deemed necessary, exercise caution and monitor patient closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Patients receiving etanercept are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (including reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral, or other opportunistic infections (including Legionellosis and Listeriosis) have been reported. Monitor closely for signs/symptoms of infection during and after treatment. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to initiating therapy in patients with chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infections who develop severe systemic illness.</b> Caution should be exercised when considering use in elderly patients, patients with chronic or recurrent infections, patients exposed to tuberculosis, patients with a history of an opportunistic infection, in patients with conditions that predispose them to infections (eg, advanced or poorly controlled diabetes), residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent infections. Do not initiate etanercept therapy in patients with an active infection, including clinically important localized infection. Patients who develop a new infection while undergoing treatment should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Lymphoma and other malignancies (some fatal) have been reported in children and adolescents receiving TNF-blocking agents, including etanercept.</b> Half of the malignancies reported in children and adolescents were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included rare malignancies usually associated with immunosuppression and malignancies not typically observed in this population. The impact of etanercept on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma and leukemia. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving etanercept. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn disease or ulcerative colitis. Melanoma, nonmelanoma skin cancer, and Merkel cell carcinoma have been reported. Perform periodic skin examinations in all patients during therapy, particularly those at increased risk of skin cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: <b>[US Boxed Warning]: Active tuberculosis (disseminated or extrapulmonary), including reactivation of latent tuberculosis, has been reported in patients receiving etanercept.</b><b> Evaluate patients for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to and during therapy. Treatment for latent tuberculosis should be initiated before use. </b><b>Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis during and after treatment. </b> Consider antituberculosis treatment if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; tests for latent tuberculosis infection may be falsely negative while on etanercept therapy. Use with caution in patients who have traveled to or resided in regions where tuberculosis is endemic. Monitor for signs and symptoms of tuberculosis in all patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcoholic hepatitis: Use with caution in patients with moderate to severe alcoholic hepatitis. Compared to placebo, the mortality rate in patients treated with etanercept was similar at one month but significantly higher after 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with a history of seizures; new-onset or exacerbation of seizures have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Wegener granulomatosis: Use is not recommended in patients with Wegener granulomatosis who are receiving immunosuppressive therapy due to higher incidence of noncutaneous solid malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Infection has been reported at a higher incidence; use caution in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Malignancies have been reported among children and adolescents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Varicella virus exposure: Patients with a significant exposure to varicella virus should temporarily discontinue therapy; treatment with varicella zoster immune globulin should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Diluent for injection may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: Some dosage forms may contain dry natural rubber (latex).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25872294\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In  an analysis of children and adolescents who had received TNF-blockers (etanercept and infliximab), the FDA identified 48 cases of malignancy. Of the 48 cases, ~50% were lymphomas (eg, Hodgkin and non-Hodgkin lymphoma) and other malignancies, such as leukemia, melanoma, and solid organ tumors, were also reported; malignancies rarely seen in children (eg, leiomyosarcoma, hepatic malignancies, and renal cell carcinoma) were also observed. Overall, in pediatric patients, the median onset of malignancy was after 30 months of therapy (range: 1 to 84 months); most of these cases (88%) were receiving other immunosuppressive medications (eg, azathioprine and methotrexate). As compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis has been previously associated with an increased rate of lymphoma. The role of TNF-blockers in the development of malignancies in children cannot be excluded. The FDA also reviewed 147 postmarketing reports of leukemia (including acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia) in patients (children and adults) using TNF-blockers. Average onset time to development of leukemia was within the first 1 to 2 years of TNF blocker initiation. Although most patients were receiving other immunosuppressive agents, the role of TNF blockers in the development of leukemia could not be excluded. The FDA concluded that there is a possible association with the development of leukemia and the use of TNF-blockers. Patients should be monitored closely for signs and symptoms suggestive of malignancy, evidence of which should result in prompt discontinuation of the medication and appropriate diagnostic evaluation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In JIA patients, rare inflammatory bowel disease has also been reported (van Dijken 2011); monitor and discontinue therapy if symptoms develop.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299288\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167863\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13284&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Etanercept may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: Etanercept may enhance the immunosuppressive effect of InFLIXimab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: Anti-TNF Agents may enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167876\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Etanercept crosses the placenta. Following in utero exposure, concentrations in the newborn at delivery are 3% to 32% of the maternal serum concentration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047264\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor improvement of symptoms and physical function assessments (eg, joint swelling, pain, and tenderness; ESR or C-reactive protein level). Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; LFTs at baseline; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167857\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Etanercept is a recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds tumor necrosis factor (TNF) and blocks its interaction with cell surface receptors. TNF plays an important role in the inflammatory processes and the resulting joint pathology of rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and plaque psoriasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167872\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~2 to 3 weeks; RA: 1 to 2 weeks; Maximum effect: RA: Full effect is usually seen within 3 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Absorbed slowly after SubQ injection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: 60%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: SubQ: Children &ge;4 years and Adolescents (JIA): Mean range: 70 to 94.8 hours (range: 31.2 to 104.8 hours) (Yim 2005); Adults (RA): 102 &plusmn; 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: RA: SubQ: 69 &plusmn; 34 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance: Children and Adolescents 4 to 17 years: 46 mL/hour/m<sup>2 </sup>(Enbrel prescribing information 1998); Adults: 160 &plusmn; 80 mL/hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167875\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Enbrel Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $730.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Enbrel SureClick Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Enbrel Mini Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Enbrel Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/0.5 mL (0.51 mL): $730.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (0.98 mL): $1,461.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F167878\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benepali (GB, IE);</li>\n      <li>Enbrel (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UA, VE, VN);</li>\n      <li>Infinatam (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akgul O, Kilic E, Kilic G, et al, &quot;Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever,&quot; <i>Am J Med Sci</i>, 2012, Dec 28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/23276893/pubmed\" target=\"_blank\" id=\"23276893\">23276893</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. <i>N Engl J Med</i>. 2000;343(22):1586-1593.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/11096165/pubmed\" target=\"_blank\" id=\"11096165\">11096165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bilgen SA, Kilic L, Akdogan A, et al, &quot;Effects of Anti-tumor Necrosis Factor Agents for Familial Mediterranean Fever Patients With Chronic Arthritis and/or Sacroiliitis Who Were Resistant to Colchicine Treatment,&quot; <i>J Clin Rheumatol</i>, 2011, 17(7):358-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/21946459/pubmed\" target=\"_blank\" id=\"21946459\">21946459</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borzutzky A, Stern S, Reiff A, et al, &quot;Pediatric Chronic Nonbacterial Osteomyelitis,&quot; <i>Pediatrics</i>, 2012, 130(5):e1190-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/23071213/pubmed\" target=\"_blank\" id=\"23071213\">23071213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Ann Rheum Dis</i>. 2004;63(12):1594-1600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/15345498/pubmed\" target=\"_blank\" id=\"15345498\">15345498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choueiter NF, Olson AK, Shen DD, et al, &quot;Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease,&quot; <i>J Pediatr</i>, 2010, 157(6):960-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/20667551/pubmed\" target=\"_blank\" id=\"20667551\">20667551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. <i>Arthritis Rheum</i>. 2003;48(11):3230-3236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/14613288/pubmed\" target=\"_blank\" id=\"14613288\">14613288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enbrel (etanercept) [prescribing information]. Seattle, WA: Immunex Corporation; November 1998.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enbrel (etanercept) [prescribing information]. Thousand Oaks, CA: Immunex Corporation; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erelzi (etanercept) [prescribing information]. Boucherville, QU: Sandoz Canada Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erelzi (etanercept) [prescribing information]. Princeton, NJ: Sandoz Inc; August 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. <i>Arthritis Rheum</i>. 2002;46(6):1443-1450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/12115173/pubmed\" target=\"_blank\" id=\"12115173\">12115173</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lovell DJ, Reiff A, Jones OY, et al, &quot;Long-Term Safety and Efficacy of Etanercept in Children With Polyarticular-Course Juvenile Rheumatoid Arthritis,&quot; <i>Arthritis Rheum</i>, 2006, 54(6):1987-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/16732547/pubmed\" target=\"_blank\" id=\"16732547\">16732547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. <i>Lancet</i>. 2000;356(9227):385-390.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/10972371/pubmed\" target=\"_blank\" id=\"10972371\">10972371</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. <i>Arthritis Rheum</i>. 2004;50(7):2264-2272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/15248226/pubmed\" target=\"_blank\" id=\"15248226\">15248226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreland LW, Baumgartner SW, Schiff MH, et al, &ldquo;Treatment of Rheumatoid Arthritis With a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein,&rdquo; <i>N Engl J Med</i>, 1997, 337(3):141-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/9219699/pubmed\" target=\"_blank\" id=\"9219699\">9219699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Ouml;zen S, Bilginer Y, Aktay Ayaz N, et al, &quot;Anti-interleukin 1 Treatment for Patients With Familial Mediterranean Fever Resistant to Colchicine,&quot; <i>J Rheumatol</i>, 2011, 38(3):516-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/21159830/pubmed\" target=\"_blank\" id=\"21159830\">21159830</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paller AS, Siegfried EC, Eichenfield LF, et al, &quot;Long-Term Etanercept in Pediatric Patients With Plaque Psoriasis,&quot; <i>J Am Acad Dermatol</i>, 2010, 63(5):762-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/20605256/pubmed\" target=\"_blank\" id=\"20605256\">20605256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paller AS, Siegfried EC, Langley RG, et al, &quot;Etanercept Treatment for Children and Adolescents With Plaque Psoriasis,&quot; <i>N Engl J Med</i>, 2008, 358(3):241-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/18199863/pubmed\" target=\"_blank\" id=\"18199863\">18199863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paller AS, Siegfried EC, Pariser DM, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. <i>J Am Acad Dermatol</i>. 2016;74(2):280-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/26775775/pubmed\" target=\"_blank\" id=\"26775775\">26775775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Portman MA, Olson A, Soriano B, et al, &quot;Etanercept as Adjunctive Treatment for Acute Kawasaki Disease: Study Design and Rationale,&quot; <i>Am Heart J</i>, 2011, 161(3):494-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/21392603/pubmed\" target=\"_blank\" id=\"21392603\">21392603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sakallioglu O, Duzova A, and Ozen S, &quot;Enercept in the Treatment of Arthritis in a Patient With Familial Mediterranean Fever,&quot; <i>Clin Exp Rheumatol</i>, 2006, 24(4):435-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/16956436/pubmed\" target=\"_blank\" id=\"16956436\">16956436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siegfried EC, Eichenfield LF, Paller AS, et al, &quot;Intermittent Etanercept Therapy in Pediatric Patients With Psoriasis,&quot; <i>J Am Acad Dermatol</i>, 2010, 63(5):769-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/20833444/pubmed\" target=\"_blank\" id=\"20833444\">20833444</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soriano A, Verecchia E, Afeltra A, et al, &quot;IL-1&beta; Biological Treatment of Familial Mediterranean Fever,&quot; <i>Clin Rev Allergy Immunol</i>, 2013, Jan 16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/23322405/pubmed\" target=\"_blank\" id=\"23322405\">23322405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Dijken TD, Vastert SJ, Gerloni VM, et al, &quot;Development of Inflammatory Bowel Disease in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept,&quot; <i>J Rheumatol</i>, 2011, 38(7):1441-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/21459936/pubmed\" target=\"_blank\" id=\"21459936\">21459936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. <i>J Clin Pharmacol</i>. 2005;45(3):246-256.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etanercept-including-biosimilars-of-etanercept-pediatric-drug-information/abstract-text/15703360/pubmed\" target=\"_blank\" id=\"15703360\">15703360</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13284 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F6655343\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F167887\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F167888\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047265\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047258\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F167868\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F167854\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F48847984\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874648\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047268\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F167883\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047267\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914269\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F167917\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F167873\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F167858\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25872294\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299288\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F167863\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F167876\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047264\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F167857\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F167872\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F167875\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F167878\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13284|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept (including biosimilars of etanercept): Drug information</a></li><li><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-patient-drug-information\" class=\"drug drug_patient\">Etanercept (including biosimilars of etanercept): Patient drug information</a></li></ul></div></div>","javascript":null}